Marc Stapley became Chief Executive Officer of Veracyte on June 1, 2021, and also serves on the company’s board of directors.
Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global operations. Prior to joining Veracyte, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.
Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina, the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. While at Illumina, he served as Chief Financial Officer, Chief Administrative Officer, and Executive Vice President over the course of seven years, where he led many functions including G&A, corporate strategy, business development, population genomics and government affairs.
Before joining Illumina, Mr. Stapley was Senior Vice President, Finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts for key acquisitions and providing oversight to the company’s largest technology investment program. Prior to that he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand.
Mr. Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales. He is a member of the board of directors of Helix, Glaukos (GKOS), and Premier Food Concepts.
How old is Marc A. Stapley?
Mr. Stapley is currently 54 years old. There are 5 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Marc A. Stapley's age.
How do I contact Marc A. Stapley?
Has Marc A. Stapley been buying or selling shares of Veracyte?
Who are Veracyte's active insiders?
Are insiders buying or selling shares of Veracyte?
In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 27,432 shares worth more than $717,186.41. The most recent insider tranaction occured on April, 1st when Director Karin Eastham sold 10,000 shares worth more than $216,500.00. Insiders at Veracyte own 2.6% of the company.
Learn More about insider trades at Veracyte. Information on this page was last updated on 4/1/2024.
